GeneGoCell Inc. published a June 2026 FAQ Developing Potential CGT Products.
Public source
Publisher name
Public post
A summary initially intended to help ourselves better grasp the three documents FDA published this year for CGT. * April 2026 draft guidance: Safety Assessment of Genome…
Company
GeneGoCell Inc.
GeneGoCell provides high-quality, innovative and fast-TAT customized solutions in GENE (NGS) and CELL (flow cytometry).
- Industry
- Biotechnology Research
- Location
- San Diego, US
- Company size
- 11–50 employees
About GeneGoCell Inc.
We are a San Diego Life Science Company supporting the Gene and Cell Therapy industry by providing one-stop custom NGS and Flow Cytometry Solutions, from assay design to data analysis and report, all from our CLIA, and GLP/GMP compliant labs. We embrace the latest technologies, innovate and optimize workflows, and forge strategic partnerships with industry leaders to offer the highest level of client support. Our service lines cover: Genome Editing Verification (GEV); and Custom NGS Services. We provide our services observing your individual needs for discretion and confidentiality. Our in-house bioinformatics team has developed our proprietary algorithms and provide unmatched support for the analysis and processing of all project data. Finally, we have supported multiple approved IND filings for our clients. This experience and our unrivaled attention to client needs makes GeneGoCell the teammate you want on the road to your own success and approval. We Value: Industry-Leading Turnaround Time Service Quality Cost-Effectiveness Genome-Editing Verification Solutions: On-Target Verification Off-Target Site Identification and Verification Translocation Identification Transgene Integration Sites and Integrity RNAseq (including mRNA and miRNA) Our GEV services are fully customizable and provide results in industry leading turn-around time with 90% of projects completed in 1 week and 100% within 2 weeks. G-Screen: Single clone genotyping (high throughput screening/selection) - From as few as 500 cells per well, with 3-day average turn-around time. Find out why our client retention is 100% Contact us today for more information or for a custom quote for service.
See moreLatest activity
Latest activity from GeneGoCell Inc.
6 signals
Products & Services
GeneGoCell Inc. launched G-GUIDE℠, its licensed and optimized GUIDE-seq workflow, providing a sample-to-report solution for genome-wide off-target identification with a validated LOD of 0.005%, native-molecule UMI barcoding, and a guaranteed two-week turnaround time.
Products & Services
GeneGoCell Inc. generated high-quality datasets across diverse cell types, including primary T cells, B cells, HEK293T cells, iPSCs, HSCs, and primary hepatocytes, using G-GUIDE℠.
Research & Knowledge
GeneGoCell Inc. published an August 2026 draft guidance on Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Biocytogen
Biocytogen published a research paper by the Penn/Carl June team tracking early CD19 CAR-T recipients with B-cell lymphoma and finding CAR transgenes persisting in some responders for 7 to 10 years.
Research & Knowledge
CellCarta
CellCarta spent a couple of days thinking about in vivo CAR-T therapies and what partners need to support them.
Research & Knowledge
TQ Therapeutics
TQ Therapeutics co-authored a perspective in Cytotherapy exploring how Europe can move from CAR-T innovation to CAR-T accessibility.
Research & Knowledge
RoukenBio
RoukenBio published a study by Zihao Wen, Mengxin Xu, Zijun Yan, and Ziren Kong in Nature, August 2026, detailing a binding-triggered release strategy for targeted anticancer agents.
Research & Knowledge
Eureka Biotechnology Co., Limited